logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

SHENZHEN INT'L (00152) Completes Issuance of 2026 Medium-Term Notes (Fifth Tranche)

date
17:37 14/09/2026
avatar
GMT Eight
Shenzhen International (00152) announced that on September 14, 2026, the company completed the issuance of the fifth tranche of its 2026 medium-term notes in the amount of RMB 1 billion, with a coupon rate of 1.65% and a term of 5 years.
SHENZHEN INT'L (00152) announced that on September 14, 2026, the company completed the issuance of the fifth tranche of its 2026 medium-term notes in the amount of RMB 1 billion, with a coupon rate of 1.65% and a term of 5 years.
Related Articles
HK Stock
KWAN YONG (09998) Issues Profit Alert, Expects Annual Net Profit Attributable to Shareholders to Increase Year-on-Year to Approximately S$19.8 Million
HK Stock
CMS (00867): Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 Receives Drug Clinical Trial Approval Notice for Systemic Lupus Erythematosus Indication
China Stock
Chutian Dragon (003040.SZ)'s controlling shareholder plans to reduce its shareholding by no more than 3%.
KWAN YONG (09998) Issues Profit Alert, Expects Annual Net Profit Attributable to Shareholders to Increase Year-on-Year to Approximately S$19.8 Million
HK Stock
CMS (00867): Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 Receives Drug Clinical Trial Approval Notice for Systemic Lupus Erythematosus Indication
HK Stock
Chutian Dragon (003040.SZ)'s controlling shareholder plans to reduce its shareholding by no more than 3%.
China Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.